Gucci Belts Brown
only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, and operating start up companies, including obtaining third party funding. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10 K for the year ended December 31, 2005 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. (ACAD) Announces Accelerated Timing Of ACP 103 Phase II Trial In Patients With Schizophrenia; Top Line Results For Complete 400 Patient Study Expected In Q1 2007 Applied Biosystems (ABI) Announces Management Change; President Resigns; CEO Tony L. White Become Interim President
ACADIA Pharmaceuticals Inc To Support Launch Of New Company Focused On Substance Abuse Therapeutics Mark R Brann Ph D To Become CEO Of Ab
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five Phase II stage clinical programs as well as a portfolio of preclinical and discovery assets directed at diseases with large unmet medical needs, including schizophrenia, Parkinson's disease, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
that may have utility in the field of substance abuse. ACADIA has agreed to increase its investment to an aggregate of $1 million upon Abbey's completion of an external equity financing. "While ACADIA's discovery platform may generate novel drug candidates with applications in substance abuse, this indication is outside of our strategic focus and we believe it can best be pursued by an independent and focused effort. Brann in forming Abbey. Dr. Koob is a Professor at Scripps Research Institute and Director of The Pearson Center for Alcoholism and Addiction Research.
for breakthrough therapeutic interventions in the field of substance abuse, but significant pharmaceutical commitment to the area has only recently emerged," said Leslie L. "Having known both Mark and George throughout their scientific careers, I believe that together they can uniquely advance this highly underserved therapeutic area. On behalf of the board and employees of ACADIA, I would like to take this opportunity to thank Mark for his vast contributions as ACADIA's founder, President, CSO, and board member. We wish him well in his new role at Abbey and we look forward to the potential for ACADIA to collaborate with this organization focused on the substance abuse area."
"I am very excited to form a company committed to delivering new therapeutic options to treat substance abuse," said Mark R. "Abbey is poised to pursue this specialty CNS area, where breakthroughs in science can be directly linked to solving major unmet medical needs in large potential markets. I am very proud of the team, technology and exciting clinical programs that we have built at ACADIA. With its strong senior management bolstered by the recent addition of Dr. Roger Mills as Executive Vice President, Development, I believe ACADIA is well positioned to execute on its rich clinical pipeline."
"Science has paved the way Ferragamo Belts Black
The Week In Review: Strong Gain; Stronger Breadth Catherine M. Burzik Named CEO Of Kinetic Concepts, Inc. (KCI)
NitroMed, Inc. (NTMD) Revises Sales And Marketing Strategy; Cuts 120 Jobs; Accelerates Development Of Extended Release BiDil(R) Menthol Cigarettes May Hook Smokers
Statements in this press release that are not strictly historical in nature are forward looking statements. These Gucci Belts Brown statements include but are not limited to statements related to the progress of and benefits to be derived from ACADIA's drug discovery and development programs, Abbey's programs, and future collaborations with and funding of Abbey Pharmaceuticals. These statements are Louis Vuitton Belt Square
Massive Layoff At Bayer New Martinsville Facility Announced Fruit Fly Study Identifies Gene Mutation That Regulates Sensitivity To Alcohol
SAN DIEGO (BUSINESS WIRE) (Nasdaq: ACAD News) today announced that it will provide initial seed funding to help establish Abbey Pharmaceuticals, a startup biotechnology company focused on medications for substance abuse. The new company will be led by Mark R. Abbey will seek external equity financing, after which it intends to collaborate with ACADIA to gain access to selected drug discovery assets Hermes Belt Tan
EXACT Sciences Corporation (EXAS) Says To Cut About 50% Jobs, Take Q4 Charge Teva Pharmaceutical Industries Limited (TEVA) Announces Planned Retirement Of President And CEO In 2007; Shlomo Yanai To Succeed As President And CEO
Gucci Belts Brown
Lv Belt Black And Grey
Hermes Belt 2017
Ferragamo Belt Tag
Hermes Belt White Stitching
Cleveland Indians Caps
Jordan Cap Gray
Gucci Belt Black With Silver Buckle
Louis Vuitton Belt For Men Price
Gucci Belt Green Snake
Lv Belt Buckle
Louis Vuitton Belt Buckle Scratch
Arizona Cardinals Hat
Hermes Belt Offer
Cap Adidas Price
Jordan Cap Jumpman